Physician profile
Michael Pan
NPI 1144607680
$2,346.45
in general payments reported to CMS, 2019-2025
14 companies · $787 in 2025
The $787 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $347 · 2023: $622 · 2024: $591 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,110.16 | 2022-2025 | Coroflow, Ensite, Xience Skypoint |
| Heartflow, INC. | $314.32 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $178.85 | 2023-2024 | |
| Genzyme Corporation | $136.08 | 2024-2025 | |
| Amgen INC. | $121.58 | 2023 | Repatha |
| Pfizer INC. | $110.66 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $77.61 | 2024 | Dupixent |
| Ucb, INC. | $68.29 | 2025 | Bimzelx |
| Abbvie INC. | $65.12 | 2025 | |
| Lilly USA, LLC | $50.33 | 2024 | Taltz, Olumiant, Zepbound |
| Leo Pharma INC. | $49.16 | 2025 | Anzupgo, Adbry |
| Stryker Corporation | $23.62 | 2025 | Flowtriever |
| Philips North America LLC | $20.34 | 2022 | |
| Incyte Corporation | $20.33 | 2025 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.